A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

Sponsor
Caliway Biopharmaceuticals Co., Ltd.
Study ID
NCT07608757
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Subcutaneous Fat

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.

Key Dates

Start date
Feb 28, 2027
Status verified
May 2026
Primary completion
Feb 29, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
250 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CBL-514 injection
    Participants will receive CBL-514 administered up to 120 mL per treatment at a 3-weeks interval for up to 4 treatments.

Primary Outcome Measure

Percentage change of abdominal fat [ Time Frame: From baseline to 4 weeks after final treatment ]

Central Contacts

Related Studies